Anthony Wile, CEO of PharmaCielo Ltd. (“the Company”) is pleased to announce that David Gordon has been appointed its Chief Corporate Officer (CCO) effective October 1, 2018.

As CCO, Mr. Gordon will be responsible for overseeing and managing relationships with news media, analysts, shareholders and regulators in addition to ensuring alignment in achieving corporate responsibility and development objectives across international operations.

David Gordon appointed Chief Corporate Officer of PharmaCielo (CNW Group/PharmaCielo)
David Gordon appointed Chief Corporate Officer of PharmaCielo (CNW Group/PharmaCielo)

“David has been an essential advisor to PharmaCielo since the earliest days of its establishment, guiding us on effective communication and corporate development strategies,” said Anthony Wile.  “As we build out our global infrastructure, I am delighted that he has agreed to bring his impressive track record and range of experience to the table on a permanent basis to help us to continue the growth and expansion of PharmaCielo throughout both the Colombian and international marketplace.”

Previously Mr. Gordon was a principal advisor to PharmaCielo as Managing Partner of Cohn & Wolfe | Canada, one of Canada’s leading communication strategy firms, and since 2013 has served as Chair of the Canadian Council of PR Firms.  Mr. Gordon was appointed to the Board of Directors of PharmaCielo Ltd. in 2016 and is a member of the Institute of Corporate Directors (ICD).

“Working with PharmaCielo and the executive team for the past several years has been an exciting period.  The emergence of a new industry that challenges convention on multiple levels including international trade, public policy and communication, to name but a few, encapsulates the various fields of challenge I have experienced throughout my career,” said David Gordon. “I look forward to continuing to work with my colleagues in Canada and Colombia to help expand to the global market the leadership that PharmaCielo has demonstrated in the Colombian marketplace.”

With 20-plus years of experience in corporate strategy and brand communications, combined with a background in public policy and political strategy following a career start in international trade and combined with an MA and MBA, David Gordon is a strong believer in being an engaged member of the community and has served on the boards of a number of non-profit organizations.

About PharmaCielo

PharmaCielo Ltd. is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo’s principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia.

The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace.

For further information:  

For further information: Media Relations: David Gordon, Tel: +1 647 259 3258,; (Colombia) Juan Manuel Cuellar, Tel: +57 310 3298776,


Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

For more information regarding the Cowen 2020 Boston Cannabis Conference please visit:

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE:ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws

Keep reading... Show less

TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced Jason Ackerman Chief Executive Officer and Executive Chairman of TerrAscend, Keith Stauffer Chief Financial Officer, and Jason Wild Chairman, will participate in three upcoming conferences:

  • Cowen’s 3rd Annual Boston Cannabis Conference, a virtual event taking place November 30-December 2 , 2020. Jason Ackerman will participate in a panel, U.S. MSOs: The West, on November 30, 2020 at 10:25 a.m. ET . Management will also host one-on-one meetings with investors throughout the conference.
  • 2020 Cantor Fitzgerald Virtual Cannabis MSO Summit, a virtual event taking place on December 15-16, 2020 . Jason Ackerman is scheduled to participate in a fireside chat on December 16 th at 1:00 p.m. ET . To register for the fireside chat: Click Here
  • 23 rd Annual Needham Virtual Growth Conference, a virtual event taking place January 11-15, 2021 . Jason Ackerman is scheduled to participate in a fireside chat on January 14, 2021 at 2:45 p.m. ET . Management will also host one-on-one meetings with investors throughout the conference. To register for the fireside chat: Click Here

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Keep reading... Show less
  • Aurora strategically positioned within two of the largest legal cannabis markets outside of Canada
  • Agreement with Israeli leader Cantek provides access to Israel’s drugstore channel
  • Finished product is co-branded under Aurora and Cantek brands


Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today it has entered into a strategic Supply Agreement (the “Agreement”) with Cantek Holdings (“Cantek”), one of Israel’s leaders in the medical cannabis field.

Keep reading... Show less